
Immune Checkpoint Inhibitor Dose Reduction: Evidence for Equal Efficacy with Improved Safety and Cost Profiles
By Donnie Yance Immune checkpoint inhibitors (ICIs, also known as ICBs) have revolutionized cancer treatment by offering durable responses across multiple tumor types. However, these breakthrough therapies come with significant challenges: high costs that limit global access, substantial toxicity profiles, and mounting evidence that currently approved doses may be higher

